M alignant melanoma is a common malignancy in dogs, representing 3% of all neoplasms and up to 7% of all malignant tumors. 1, 2 The oral cavity is the most common site (56%); other frequent locations include the lips (23%), the skin (11%), the digits (8%), and the orbit (2%). 3 Most cutaneous canine melanomas are benign, in contrast to the human equivalent; however, melanoma in the oral cavity is always considered malignant 3, 4 and is the most common oral cancer in dogs. 3, 5 Most canine oropharyngeal, uveal, ungual, and mucocutaneous melanomas are aggressive, with severe local infiltration and a high metastatic potential to lymph nodes, lungs, liver, and kidneys. 3, 6, 7 The etiology of melanocytic tumors in dogs is largely unknown, but as the oral cavity and haired skin are the most common places for these tumors, an etiology involving ionizing sunlight is unlikely. Breed seems to influence both incidence and prognosis, suggesting the contribution of genetic factors. 2, 4 Genetic and molecular factors that have been associated with canine malignant melanoma include p53, metallothionein, RB-1, PTEN, N-ras, cyclin kinase inhibitors, and some angiogenic factors. [7] [8] [9] [10] It is interesting to note that the same factors are also involved in the pathogenesis of human melanomas, which supports the utility of comparative medicine, [9] [10] [11] and suggests that canine malignant melanoma is a good spontaneous clinical model for the development of new therapies for humans. [12] [13] [14] [15] [16] Malignant melanoma is primarily a disease of older dogs. The mean age of onset varies between 9 and 11 years. 4, 17 Stage is an important prognostic factor for both canine and human melanomas. Dogs with World Health Organization (WHO) 18 stages II-IV have a reported median survival of <5 months despite radical surgical resection of the local tumor. [19] [20] [21] In human patients with distant metastases (stage IV), the median survival time is <10 months, and most of these patients die of the disease. 22 Both human and canine melanomas respond poorly to chemotherapy. 23, 24 In contrast, immunotherapy has resulted in important recent proof-of-concept advances. 25, 26 CD40 Ligand (CD40L) is a potent T-helper 1 immune stimulator shown to trigger robust antitumor reactions. [27] [28] [29] CD40L belongs to the tumor necrosis factor (TNF) gene superfamily and is expressed under inflammatory conditions by immune cells and by stressed cells of nonhematopoietic origin. 30 Stimulation of CD40 in antigen-presenting cells such as dendritic cells leads to their maturation and increased capacity to present antigens to T cells, as well as to their secretion of cytokines, such as interleukin 12 and IFNg. CD40L-stimulated dendritic cells activate effector cells in the immune system such as cytotoxic T lymphocytes, natural killer cells, and M1 macrophages, which are all important in antitumor immunity. 31 Further, CD40L-mediated engagement of CD40 on tumor cells can induce apoptosis, 29 and clinical trials have provided encouraging safety data. Although some antitumor activity was seen, these trials also demonstrated that systemic delivery of recombinant CD40L resulted in adverse events from nontarget organs. [32] [33] [34] [35] [36] Therefore, the therapeutic use of systemic recombinant CD40L may not be optimal, and local production, aiming for higher local and lower systemic concentrations, using a gene therapy approach may be safer. Adenoviral vector-mediated transfer of CD40L (AdCD40L) to the tumor area has been shown to have good response in high-grade bladder carcinoma, in both preclinical models 29, 37, 38 and a human clinical trial. 39 A case report also suggested the feasibility of this approach in treating spontaneous melanoma in dogs, by showing that human CD40L could stimulate dog immune cells. 40 We report a pilot study treating 19 dogs for spontaneous malignant melanoma with AdCD40L immunotherapy. The objectives of the study were to further investigate whether AdCD40L could be administered to dogs in a safe and simple way, to examine immune activation in tumor tissue after AdCD40L treatment, to gather evidence of systemic responses to immunotherapy, and to evaluate the preliminary efficacy of the treatment by determining the best overall response (BOR).
MATERIALS AND METHODS

Study Design
This is a pilot study using AdCD40L immunotherapy in client-owned dogs with spontaneous malignant melanoma. Between May 2005 and June 2011, 19 dogs with malignant melanoma had undergone local adenovector human CD40L (AdCD40L) immunogene treatment in a small animal clinic at the University Animal Hospital, Swedish University of Agricultural Sciences. The objectives were to evaluate the safety, immunologic responses, and antitumor activity. AdCD40L therapy and sample collection were approved by the Swedish Animal Ethical Committee and the Swedish Animal Welfare Agency. Production of the AdCD40L vectors was performed as previously described. 40 Tumors were staged according to WHO's TNM Classification of Tumours in Domestic Animals 18 in which stage I tumors are <2 cm in diameter, with negative nodes; stage II tumors are 2-4 cm in diameter, with negative nodes; stage III tumors are >4 cm and/or with positive nodes; and stage IV is distant metastatic disease). The diagnosis was confirmed by histopathologic examination of biopsies in all cases but 1 (dog 18), which was diagnosed by fine-needle aspirate. Each tumor was measured by a ruler in 2 dimensions, and fine-needle aspirates were taken from enlarged lymph nodes. All dogs also had 3-view thoracic radiographs to investigate the presence of pulmonary metastases. In some cases, abdominal ultrasound, magnetic resonance imaging, or computed tomography was performed to evaluate distant metastases. A complete blood count and routine blood chemistry examination were performed before initiating therapy to evaluate the status of the patient and before each treatment to detect any changes during treatment. Ten of the dogs also had gel electrophoresis performed to detect changes in circulating antibodies during treatment.
Tumor tissues sampled before and after treatment were investigated for immune cell infiltration in 11 of the dogs. Histologic staining was performed according to the method described earlier. 40 Briefly, the tumor specimens were fixed in a buffered 10% paraformaldehyde solution and embedded in paraffin. Tissue sections were prepared from the paraffin-embedded tissues for routine hematoxylin-eosin staining and immunohistochemical analysis and subjected to staining procedures with either monoclonal mouse anti-human CD3 (clone F7.2.38; Dakocytomation, Glostrup, Denmark) or monoclonal mouse anti-human CD79 acy (clone HM57; Dakocytomation). The complex expressions were visualized using the Dakocytomation EnVision + R system HRP anti-mouse (K 4001), with diaminobenzidine as the substrate. Nuclear counterstaining was performed with Mayer hematoxylin.
Detection of Serum Cytokines (ELISA)
The levels of the proinflammatory cytokine TNF-a, the chemokine IL-8, the T-cell response suppressor of IL-10 were analyzed in the serum of 6 dogs before therapy and 3 weeks after therapy using Quantikine ELISA kits from RnD Systems, Abingdon, UK accordingly to company protocol. All samples were analyzed in triplicate.
Detection of Neutralizing Antibodies
Serum from 6 dogs was analyzed before and 3 weeks after treatment for the level of neutralizing antibodies against human adenovirus serotype 5. The neutralizing titer was defined as the dilution of serum that blocked a minimum of 80% of gene transfer. 41 
Clinical Treatment
AdCD40L intratumoral injections (n = 1-6) on a 7-day cycle were followed by cytoreductive surgery in 9 cases, and 10 cases had immunotherapy only. None of the dogs received radical surgery because it was either declined by the owner or not possible because of the extent or localization of the tumor.
Dogs were sedated with medetomidine and butorphanol injections before treatment and also had xylocaine applied locally at the injection site. Blood sampling was performed before treatment at each visit. Blood samples were taken for a complete blood count, routine chemistry examination, and gel electrophoresis. AdCD40L was injected into the tumor and in 3 cases in both the tumor and the local metastasized lymph node. The AdCD40L vector was prepared by diluting 37 mL of stem solution (viral titer 7 Â10
10 pfu/mL) to a volume of 1 mL with sodium chloride. Between 1 and 3 mL AdCD40L was injected each time using a syringe and a 25 G needle. All dogs received an atipamezole injection to reverse the sedation after treatment.
The dogs were dismissed from the clinic immediately after each treatment and lived at home with their owners.
Clinical Response and Patient Evaluation
Response to therapy was categorized in accordance to WHO criteria as complete response (complete regression of measurable soft tissue disease), partial response (>50% but <100% regression in 1 dimension of measurable soft tissue disease), stable disease (r50% regression of soft tissue disease or r25% progression), and progressive disease (>25% increase in measurable disease or appearance of new lesions). BOR was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Adverse events after treatment were graded according to the Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE), version 1.0. 42 Dogs were rechecked for as long as clinically necessary to determine survival for each dog. Overall survival (OS) was defined as the time from first treatment with AdCD40L until subsequent death. All dogs were followed up until death. Tumor tissue before and after treatment was histologically examined for infiltration of immune cells in 11 of the dogs.
Statistical Analyses
Event-time distributions were estimated using the Kaplan-Meier method. Median survival was calculated with the Kaplan-Meier product limit method using JMP (SAS Institute Inc., Cary, NC) statistical discovery software. Cox proportional hazard models stratified according to age, weight, sex, breed, stage, melanotic versus amelanotic primary tumor, primary tumor location, presence of local or/and distant metastases, number of AdCD40L treatments, adverse effects after treatment, whether or not the dog had undergone surgery after treatment, histologic tumor type, histologic tumor response, and grade of infiltration of immunogenic cells in tumor tissue after therapy. A factor with a P-value <0.05 was considered significant. Dogs were censored if they were still alive at manuscript submission, and the dog euthanized because of seizures 20 days after first treatment was also censored. The 3 dogs with stage I disease were not included in the Cox proportional hazard analyses. Two Kaplan-Meier survival graphs were calculated, 1 including the stage I dogs and 1 excluding the stage I dogs.
The levels of serum cytokines and neutralizing antibodies were analyzed using the Wilcoxon matched-pairs signed rank test in GraphPad Prism (GraphPad Software, La Jolla, CA).
RESULTS
Patient Characteristics
The group consisted of 14 oral, 4 cutaneous, and 1 conjunctival melanoma (Table 1) . Dogs were between 4 and 14 years old when therapy started, with a mean and median age of 10.2 and 11 years, respectively. The median weight was 24 kg, and mean weight was 24.2 kg, ranging from 5.2 to 40 kg. Ten of the dogs were male (1 neutered) and 9 were female (2 spayed). According to the WHO staging scheme 4 patients had stage IV disease, 10 had stage III, 2 had stage II, and 3 patients had stage I disease. 18 Thirteen dogs had undergone surgery before treatment, but 10 relapsed and 3 had tumor cells present at the margins after surgery. One dog had undergone chemotherapy (paclitaxel) before treatment, but reached no tumor control, and 5 dogs had no prior treatment before the first injection of AdCD40L.
Clinical Response to AdCD40L Treatment
The BOR according to WHO response criteria included 5 complete responses, 8 partial responses, and 4 stable and 2 progressive disease statuses (Table 1) . In all cases, a clinically evident inflammation occurred in the tumor after the course of AdCD40L injections, with initial edema often followed by increased firmness and signs of organization. In 10 dogs the tumor was ulcerated after treatment, and in 2 dogs (patients 2 and 14) the tumor regressed markedly after therapy (Fig. 1) . At submission, Kaplan-Meier median survival was 160 days (range, 20-1141 d), and the mean survival time was 335 days, including the 3 stage I dogs, with 3 of the treated dogs still alive. If the 3 dogs in stage I were excluded, the KaplanMeier median survival time would be 131 days and the mean survival time 185 days (Fig. 2) . Three of the 16 deceased dogs (patients 1, 4, 6) were euthanized for causes other than melanoma.
The variables that had statistically significant association or effect on OS using Cox proportional hazard analyses were breed (P = 0.0168), stage (P = 0.0119), age (P = 0.0300), weight (P = 0.0007), number of AdCD40L treatments (P = 0.0366), surgery after treatment (P = 0.0114), and presence of metastases (P = 0.0022).
Immunologic Response
Patient 16, with metastases in the brain, was euthanized 20 days after initiation of treatment because of seizures presenting after the second AdCD40L treatment. On histopathology, a marked T-cell infiltrate was seen in the posttreatment samples from the metastases in the brain (Figs. 3A, B) . Only 1 dog (patient 2) of 10 that were tested had a posttreatment increase in the acute-phase proteins analyzed by gel electrophoresis.
The levels of the proinflammatory cytokine TNF-a, the chemokine IL-8, and the T-cell response suppressor IL-10 were analyzed in the serum of 6 dogs before therapy and 3 weeks after therapy. TNF-a and IL-10 levels were below detection limits both before and after therapy, as is usual in canines. However, the chemokine IL-8 was present in all dogs before and after AdCD40L treatment. IL-8 is present in healthy canine serum at a mean concentration of 1307 pg/mL (according to the manufacturer of the Quantikine IL-8 kit), and our data therefore suggest that in all but 1 dog pretreatment levels were elevated, as similarly reported in human patients 43 (Fig. 4) . In 1 patient there was a clear decrease in serum IL-8, whereas in other patients the level remained relatively stable.
As reported for human patients treated with adenovirus, 39 there was an increase in neutralizing antibody titer in all dogs (Fig. 4) . No patients had detectable preexisting titers.
Safety and Toxicity
Adverse effects were seen in 8 of the dogs. Mild transient fever developed in 7, and 5 had mild anorexia. Three dogs had swelling at the injection site, which was more easily seen in the 2 dogs that received AdCD40L therapy in a metastasized lymph node. Two dogs had a mild and transient increase in liver enzymes after treatment; 1 had a grade 2 increase in both alanine amino transferase and alkaline phosphatase, and another had a grade 2 rise in alanine amino transferase (graded according to the VCOG-CTCAE after chemotherapy or biological antineoplastic therapy in dogs and cats version 1.0). 42 No other adverse effects were noticed. The adverse reactions after AdCD40L injection seemed to decline after 1 or 2 treatments, which corresponded to an increase in adenovirus-specific neutralizing antibodies in serum after therapy (Fig. 4) .
Histopathology
Tissue collected, by biopsy or surgery, from close to the injection site from 11 of the dogs both before and after treatment (Table 2) showed 5 epithelioid melanomas, 3 spindle cell melanomas, and 3 mixed-type melanomas. The histologic diagnosis of melanoma was based on the histologic classification of tumors in domestic animals according to cytologic appearance, number of mitoses, pleomorphism, and presence of anaplastic and poorly differentiated cells. 17 However, the histologic evaluation is not always a reliable prognostic indicator; rather the combination of oral location and morphology indicating malignancy supports a bad prognosis of melanoma in a dog.
Ten melanomas were grade 3 (the most malignant) and 1 was grade 2 (intermediate). Immune activation by AdCD40L therapy was seen in several of the patients. An 
DISCUSSION
A phase I/II trial was recently completed in which local AdCD40L therapy was used in human bladder cancer, 39 and a trial of its use for malignant melanoma is currently being conducted at the Uppsala University Hospital in Sweden. Similar to our results in canine melanoma patients, AdCD40L therapy in bladder cancer patients caused marked local immune stimulation in the bladder wall, and the adverse effects noticed were mild. 39 AdCD40L therapy was safe and easy to administer to the dogs, and only mild adverse effects were noticed after treatment. The significant rise in neutralizing antibodies after 3 treatments seemed to correlate with the posttreatment reactions seen clinically. The reactions were most prominent after first and second treatments and declined as treatment progressed, which might indicate that the adverse events were related to a degree of systemic exposure (blocked after the induction of antibodies) to virus despite local injection. Alternatively, repeated injection could have resulted in tolerization of antiadenoviral T cells.
In an earlier study published in 2008, 40 we reported that human CD40L was efficiently expressed after AdCD40L vector transduction. Coculturing 1 Â10 6 canine T cells at a 1:1 ratio with the AdCD40L-transduced dog cell lines induced IFNg secretion as detected by ELISA. When stimulating the same T cells with untransduced or Ad(CMV-GFP)-transduced cell lines, only background amounts of IFNg were measured. As positive controls, canine T cells were stimulated for 24 hours with the potent polyclonal T-cell activator Concavalin A, and such T cells One dog developed seizures, possibly caused by inflammation and swelling due to brain metastasis. This coincided with an acute profound generalized lymphadenopathy just days after the second treatment. It is interesting to note that the brain lesion was infiltrated with immune cells despite not being injected with AdCD40L, suggesting that local intratumoral injection of AdCD40L may trigger systemic antitumor responses able to target distant metastases.
Elevation of serum globulins (analyzed by gel electrophoresis) showed not to be a major finding in this study, despite clearly triggering an inflammatory reaction after treatment with lymphadenopathy and occasionally transient pyrexia. The reason for not seeing more dogs with elevations in globulins could be because of the sequence of sampling, as these are acute-phase proteins and in circulation for a very short time.
The reported median survival time for dogs with stage II melanoma treated with surgery alone is <5 months, and in dogs with grade III or IV it is <2-3 months. 12, 19, 20 The survival for dogs with stage II, III, or IV melanoma in this pilot study was 4 months, comparing favorably to earlier reports. It is noteworthy that one of the entry criteria for this study was the unfeasibility of radical surgery, which further emphasizes the unusually long survival seen in some patients. However, a randomized study would be needed to confirm the reproducibility of the treatment benefits.
Eleven of the dogs had tumors that relapsed after surgery, and 1 dog had a tumor refractory to chemotherapy. Relapsed tumors must be considered more resistant to treatment than naive ones. Thirteen dogs had metastases at the beginning of therapy, and none of them received radical surgical treatment after AdCD40L treatment. The 2 dogs with stage II disease were both alive at 460 and 420 days, respectively, which is rare for stage II patients treated with surgery alone. 44 The statistically significant associations between OS, stage (higher stages indicate lower OS), and the presence of metastases (dogs with metastases have lower OS) at the beginning of therapy are consistent with earlier reports. 20, 21, 45 Breed was shown in earlier trials, as in ours, to be prognostic for clinical outcome. 46 Age was correlated with prognosis, with worse prognosis for older dogs, but this could be biased if owners are more prone to euthanize an older dog and thereby shorten the OS. Surgery after treatment showed a positive correlation to OS. This could 1  Epithelioid  3  0  2  IRz  6  Spindle  3  1  2  IR  7  Epithelioid  3  1  3  Cy  9  Spindle  3  0  0  NR8  10  Mixed  3  0  2  C  11  Epithelioid  3  1  2  NR  12  Mixed  2  0  1  IR  13  Spindle  3  0  2  C  14  Epithelioid  3 be because lowering the tumor burden helps the prognosis, or it could be that this result is biased, as cases with a more promising prognosis may be more likely to undergo adjuvant surgery. A strong association was seen for weight. Dogs weighing 10-30 kg had a higher risk than dogs weighing >30 kg and those weighing <10 kg. This could also be a biased finding because of both the small patient group and the fact that the higher-staged dogs were in the intermediate-weight group. However, there has been a discussion about whether smaller dogs are at higher risk, as the WHO staging system based on tumor size is the same for all dogs regardless of their size. This means that a smaller dog would have a proportionally bigger tumor load than a large dog with a tumor of a similar size. 44 Like human melanoma, the canine disease may be susceptible to many forms of immunotherapy. Bergman et al 13, 47 have shown positive clinical effects in their studies using xenogenetic human tyrosinase DNA, and this vaccine was granted a full license approval by the United States Department of Agriculture in 2010. Other studies have used lipid-complexed plasmid DNA encoding staphylococcal enterotoxin B plus either GM-CSF or IL-2, lipid-complexed plasmid DNA encoding staphylococcal enterotoxin A and canine IL-2, and systemic delivery of liposomeencapsulated muramyl tripeptide alone or in conjunction with GM-CSF. 12, 48, 49 In these trials, survival ranged from weeks to >500 days. Some cases indicated regression of pulmonary metastases. Toxicity was generally low, and effects were mainly transient fever and diarrhea.
Because of the similarities between canine and human malignant melanoma, the disease represents an excellent comparative model for evaluating new therapies and for studies of tumor biology. Dogs may be superior to traditional murine models as dogs are generally outbred, immune-competent, similar in weight to humans, and exposed to the human environment. 50 Canine patients coming to the clinic have tumors of spontaneous origin, which also improves their value as comparative models over xenografted or genetically engineered rodents. The AdCD40L vector is easy to administer with intratumoral or peritumoral injections, typically shows only minor side effects, and, most importantly, generates antitumor responses both locally at the injection site and in peripheral metastases. The results of this pilot study warrant a prospective trial of malignant canine melanoma treated with fixed numbers of AdCD40L injections and standardized follow-up protocols including stratification for surgery. Ultimate proof of efficacy would require randomization to injections with placebo or recombinant human CD40L. Nevertheless, our results suggest that local AdCD40L therapy is safe and can indeed be beneficial for dogs with malignant melanoma. Despite the fact that stage I disease carries a favorable prognosis with surgery alone, stage I tumors localized in certain areas could severely affect the dog's quality of life after surgery. Hence, in certain circumstances adjuvant immunotherapy may be indicated to ameliorate surgical trauma, as smaller margins might be acceptable if stage I disease is treated with AdCD40L before surgery. Finally, our data lend support to testing the approach in human malignant melanomas as well.
